Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial

What Was Tested

The paper reports a study of Oxytocin and Vasopressin, published as a randomized controlled trial.

The researchers aimed to use 3,4-methylenedioxymethamphetamine (MDMA, also known as ecstasy), a strong activator of the central oxytocinergic system, as a biochemical and psychoactive provocation test to investigate oxytocin deficiency in patients with arginine vasopressin deficiency (central diabetes insipidus).

Why It Was Studied

Disruptions of the hypothalamic-pituitary axis can cause an arginine vasopressin deficiency, also known as central diabetes insipidus.

Swiss National Science Foundation, Swiss Academy of Medical Sciences, and the G&J Bangerter-Rhyner Foundation.

Who Took Part

This single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial included patients with arginine vasopressin deficiency (central diabetes insipidus) and healthy controls (matched 1:1 by age, sex, and BMI) and was conducted at the University Hospital Basel, Basel, Switzerland.

Participants and investigators assessing the outcomes were masked to assignment.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Random assignment meant chance, not the researchers, decided who got Oxytocin and who got the comparison, which limits bias.

As a double-blind Oxytocin study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Oxytocin, giving a reference point.

Each person switched between Oxytocin and the comparison at some point, usually with a gap in between.

Oxytocin concentrations were measured at 0, 90, 120, 150, 180, and 300 min after MDMA or placebo.

The primary outcome was the area under the plasma oxytocin concentration curve (AUC) after drug intake.

The AUC was compared between groups and conditions using a linear mixed-effects model.

Subjective drug effects were assessed throughout the study using ten-point visual analogue scales.

Acute adverse effects were assessed before and 360 min after drug intake using a 66-item list of complaints.

What Was Measured

Topics PubMed links to this paper include N-Methyl-3,4-methylenedioxyamphetamine, Diabetes Insipidus, Neurogenic, Oxytocin, Case-Control Studies, Arginine and Diabetes Mellitus.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Oxytocin and Vasopressin.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (The lancet. Diabetes & endocrinology), a journal based in England.

More context: the Oxytocin compound page and the Vasopressin compound page, all human trials.